In general, ERβ activity is considered antagonistic to that of ERα when both receptors co-expressed together in a cell [10]; thus, activation of ERβ by specific agonists is suggested to be a feasible treatment option for BC, including TNBC [11]. This evidence concerns the gene ESR2 and breast cancer.